【摘要】：目的:觀察甜夢口服液聯合帕羅西汀治療圍絕經期抑郁癥的療效和安全性。方法:85例圍絕經期抑郁癥女性患者隨機分為對照組(41例)和觀察組(44例)。對照組患者每日早餐后口服鹽酸帕羅西汀片20 mg,每日1次;觀察組患者在對照組治療的基礎上給予甜夢口服液10 mL,每日早晚各1次。兩組均連用8周。觀察兩組患者的臨床療效,治療前后圍絕經期綜合量表(Kupperman)評分、漢密爾頓抑郁量表(HAMD)評分、腦源性神經營養(yǎng)因子(BDNF)水平及不良反應發(fā)生情況。結果:對照組和觀察組各有1、2例患者失訪。兩組患者總有效率、不良反應發(fā)生率比較,差異均無統計學意義(P0.05)。治療后,兩組患者Kupperman評分、HAMD評分均顯著低于同組治療前,隨時間延長逐漸降低,且觀察組患者治療第8周時Kupperman評分、治療第2周時HAMD評分均顯著低于對照組;兩組患者BDNF水平均顯著高于同組治療前,隨時間延長逐漸升高,且觀察組顯著高于對照組,差異均有統計學意義(P0.05或P0.01)。結論:甜夢口服液聯合帕羅西汀治療圍絕經期抑郁癥的療效和安全性與單用帕羅西汀相當,但在改善癥狀、升高BDNF方面優(yōu)于單用帕羅西汀。
[Abstract]:Objective: to observe the efficacy and safety of Tianmeng oral liquid combined with paroxetine in the treatment of postmenopausal depression. Methods: 85 female patients with peri-menopausal depression were randomly divided into control group (41 cases) and observation group (44 cases). The patients in the control group were treated with paroxetine hydrochloride once a day for 20 mg, after breakfast, while the patients in the observation group were treated with sweet dream oral liquid once a day for 10 mL,. Both groups were treated for 8 weeks. The clinical efficacy, (Kupperman) score, (HAMD) score of Hamilton depression scale, the level of brain-derived neurotrophic factor (BDNF) and the incidence of adverse reactions were observed before and after treatment. Results: there were 12 cases in control group and 2 cases in observation group. There was no significant difference in the total effective rate and the incidence of adverse reactions between the two groups (P0.05). After treatment, the Kupperman score and HAMD score of the two groups were significantly lower than those of the same group before treatment, and gradually decreased with the prolongation of time. The Kupperman score of the observation group was significantly lower than that of the control group at the 8th week of treatment and the HAMD score at the second week of treatment. The level of BDNF in the two groups was significantly higher than that in the same group before treatment, and gradually increased with the prolongation of time, and the observation group was significantly higher than the control group, the difference was statistically significant (P0.05 or P0.01). Conclusion: the efficacy and safety of Tianmeng oral liquid combined with paroxetine in the treatment of peri-menopausal depression is similar to that of paroxetine alone, but it is superior to paroxetine alone in improving symptoms and increasing BDNF.
【作者單位】： 咸寧市中心醫(yī)院藥劑科;咸寧市中心醫(yī)院神經內科;
【分類號】：R749.4

【相似文獻】

相關期刊論文 前10條

1 倪俊芝;;甜夢口服液輔助治療抑郁癥療效觀察[J];中草藥;2007年07期

2 孫青,李鐵臣;甜夢口服液的臨床療效觀察[J];河南中醫(yī);1998年01期

3 李愛云;;甜夢口服液治療無癥狀性腦血管病患者焦慮狀態(tài)的臨床觀察[J];中草藥;2006年05期

4 丁文濤;;甜夢口服液治療失眠伴陽痿癥的臨床觀察[J];中國醫(yī)藥導報;2007年20期

5 王尚紅;項春蘭;何巖;張穎;;“甜夢口服液”治療失眠的臨床觀察[J];中國民康醫(yī)學;2008年01期

6 劉津;;甜夢口服液調節(jié)自主神經系統失衡的療效觀察[J];中草藥;2010年07期

7 翟慕遠,郭先敏,白念蘭,崔英光;甜夢口服液治療65例神經衰弱的療效觀察[J];甘肅中醫(yī)學院學報;1998年01期

8 趙濱太;甜夢口服液治療腦血管疾病的臨床療效觀察[J];藥膳食療研究;1999年02期

9 戴保賢,張流忠;甜夢口服液治療神經衰弱癥的臨床觀察[J];現代中西醫(yī)結合雜志;2003年06期

10 劉繼芳;王洪華;;甜夢在神經科的臨床應用[J];亞太傳統醫(yī)藥;2006年12期

相關會議論文 前4條

1 宓思寬;胡曉峰;;甜夢治療抑郁癥的方藥分析及臨床研究[A];中國中西醫(yī)結合學會第七屆精神疾病學術討論會論文匯編[C];2002年

2 胡曉峰;;甜夢治療失眠癥的藥理及臨床研究[A];第四次全國中西醫(yī)結合神經系統疾病學術研討會論文集[C];2002年

3 劉繼芳;;甜夢膠囊(口服液)在神經科的臨床應用[A];第九次全國中西醫(yī)結合虛證與老年病學術會議論文集[C];2007年

4 周正保;劉家林;;“甜夢口服液”治療神經衰弱50例臨床報告[A];第八次全國中西醫(yī)結合精神疾病學術研討會論文集[C];2005年

相關重要報紙文章 前1條

1 ;甜夢口服液可治療腦梗死后焦慮癥[N];中國中醫(yī)藥報;2004年

相關碩士學位論文 前2條

1 張成奇;甜夢口服液聯合米氮平片治療抑郁狀態(tài)伴頑固性失眠(脾腎兩虛型)的療效觀察[D];河北醫(yī)科大學;2015年

2 康紫厚;甜夢口服液聯合帕羅西汀治療缺血性中風后焦慮抑郁共�。I虛證）的臨床研究[D];河南中醫(yī)學院;2014年

，

本文編號：2393643